GlassScriptPhysician profile
Karen E Rehder
NPI 1467492215
$659.51
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $202.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $119.15 | 2019-2020 | |
| Astellas Pharma US INC | $104.44 | 2019-2020 | |
| Pfizer INC. | $91.83 | 2019-2020 | |
| Abbvie INC. | $67.57 | 2019-2020 | |
| Therapeuticsmd, INC. | $67.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $66.97 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $41.97 | 2019 | |
| Mylan Pharmaceuticals INC. | $32.31 | 2019 | |
| Allergan, INC. | $27.53 | 2019-2020 | |
| Avion Pharmaceuticals | $14.11 | 2019 | |
| Radius Health, INC. | $13.38 | 2019 | |
| Lilly USA, LLC | $13.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Rehder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.